Under the state’s new drug price transparency law, the Green Mountain Care Board used state Medicaid claims data to assemble a list of drugs whose sticker prices have gone up by 15 percent in one year, or by 50 percent in five years.
As a result of GMCB’s investigation, the attorney general’s office has asked 10 pharmaceutical companies by Oct. 1 to submit information that justifies their prescription price increases to the state.
Below are the 10 drugs being investigated and their rate-of-increase during the last five years. They have been listed alphabetically.
- Abilify — 55.3 percent
- Crestor —75.9 percent
- Doxycycline hyclate —4,787.6 percent
- Enbrel —92.7 percent
- EpiPpen — 205.5 percent
- Humira — 113.8 percent
- Lantus — 89.8 percent
- Latuda — 99.7 percent
- Permethrin — N/A
- Prevacid — 103.3 percent
More articles on finance issues:
CHI to shutter Washington state hospital
5 must-reads on bundled payments
10 statistics and findings on medical debt
